發(fā)布時(shí)間：2018-03-30 14:50

  本文選題：KIT變異　切入點(diǎn)：伊馬替尼　出處：《中國腫瘤生物治療雜志》2017年03期

【摘要】：目的:旨在探討酪氨酸激酶抑制劑伊馬替尼在KIT突變/擴(kuò)增的晚期黑色素瘤患者中的療效及安全性。方法:回顧性分析2009年11月至2015年9月北京大學(xué)腫瘤醫(yī)院腎病黑色素瘤科78例KIT突變/擴(kuò)增的晚期黑色素瘤患者的臨床資料,患者接受伊馬替尼口服(400 mg/日)治療,直至疾病進(jìn)展或發(fā)生不能耐受的不良反應(yīng)。結(jié)果:78例患者可評價(jià)療效。全組患者客觀緩解率22.4%,疾病控制率60.6%。17例部分緩解患者中,有11例為11或13號(hào)外顯子突變。全組患者中位無疾病進(jìn)展時(shí)間3.9個(gè)月(95%CI:2.1~5.8個(gè)月),中位總生存時(shí)間13.2個(gè)月(95%CI:10.1~16.3個(gè)月);1年生存率57%,2年生存率36%,3年生存率19%。最常見的不良反應(yīng)包括水腫、乏力、食欲減退、皮疹、粒細(xì)胞下降(發(fā)生率均≥10%),未發(fā)現(xiàn)致命性藥物不良反應(yīng)。結(jié)論:伊馬替尼治療KIT突變/擴(kuò)增的晚期黑色素瘤具有一定的療效,且安全性良好。
[Abstract]:Objective: to investigate the efficacy and safety of imatinib, a tyrosine kinase inhibitor, in patients with advanced melanoma with KIT mutation / amplification. Methods: from November 2009 to September 2015, the kidney of Peking University Cancer Hospital was retrospectively analyzed. Clinical data of 78 patients with Advanced melanoma with KIT mutation / Amplification in melanoma. The patients were treated with imatinib (400 mg/) until the disease progressed or an intolerable adverse reaction occurred. Results the curative effect could be evaluated in 78 patients. The objective remission rate was 22.4and the disease control rate was 60.6.17 partial remission patients. There were 11 cases of exon 11 or 13 mutation. The median time of disease progression was 3.9 months and 95% CI: 2.1 ~ 5.8 months. The median survival time was 13.2 months. The median survival time was 13.2 months. The median survival time was 13.2 months. The 1-year survival rate was 57, the 2-year survival rate was 366,the 3-year survival rate was 199.The most common adverse reactions included edema. Fatigue, anorexia, rash, granulocyte decline (incidence 鈮，

本文編號(hào)：1686398